Periventricular leukomalacia (PVL) is a condition characterized by damage to the white matter of the brain, particularly in the periventricular region, which is located around the ventricles of the brain. The condition is most often found in premature infants and is associated with a lack of oxygen to the brain, leading to necrosis of myelinated fibers. The white matter abnormalities may manifest as multiple small cystic lesions, and the condition is strongly associated with the development of future neurological disorders, including movement disorders and cognitive impairment.
History of the disease and interesting historical facts
The first descriptions of periventricular leukomalacia date back to the mid-20th century, when doctors began actively studying the consequences of prematurity and hypoxia in newborns. Important studies conducted in the 1980s led to a better understanding of the mechanisms of pathogenesis of this condition. A group of researchers led by N. D. Benjashi identified a link between PVL and perinatal factors, such as maternal infectious diseases, as well as specific conditions of delivery. Technological advances in neuroimaging played an important role in the study of PVL, allowing more accurate identification of changes in brain tissue in newborns and young children.
Epidemiology
The epidemiology of periventricular leukomalacia shows that the disease is observed in 20-30% premature infants weighing less than 1500 g. Analysis of epidemiological data indicates an increase in the incidence in recent decades, which is associated with an increase in the survival of premature infants. Studies conducted in European and American countries note that PVL is more common in children born with severe medical pathology, such as cerebral hypoplasia or other neonatal pathologies. Prognosis for the interaction of the disease with neurological complications in the long term also remains the subject of active research.
Genetic predisposition to this disease
According to current research, genetic predisposition to periventricular leukomalacia may be associated with several known mutant genes. In particular, interactions with genes responsible for myelination, such as the MAG (myelin associated glycoprotein) gene and the PLP1 (proteolipid protein 1) gene, are noted. In addition, at the moment there is information about a possible connection of the disease with mutations affecting cerebral circulation and vascular function. However, genetic predisposition requires further study to determine the exact mechanisms through which genetic factors influence the development of PVL.
Risk factors for the development of this disease
There are a number of risk factors that may contribute to the development of periventricular leukomalacia. These include:
- Prematurity, especially when the pregnancy term is less than 32 weeks;
- Low birth weight;
- Premature birth;
- Infections during pregnancy, such as osteomyelitis or chorioamnionitis;
- Hypoxia and asphyxia during childbirth;
- Systemic diseases of the mother, such as diabetes or hypertension;
- 17-OH-progesterone, used to prevent preterm labor, may have a negative effect on myelination;
These factors may interact with each other to increase the likelihood of developing PVL.
Diagnosis of this disease
Diagnosis of periventricular leukomalacia includes several key steps:
- Main symptoms: In some cases, newborns may experience neurological disorders such as muscle weakness, reflexes that are not normal, or difficulty moving.
- Laboratory tests: General and biochemical blood tests, as well as microbiological studies to determine the presence of infectious agents.
- Radiological examinations: Ultrasound examination (US) of the brain, which is the main diagnostic method; magnetic resonance imaging (MRI) for a more detailed study.
- Other types of disease diagnostics: Clinical observations and assessment of the patient's neurological status; if necessary, diagnostic lumbar puncture to assess cerebrospinal fluid.
- Differential diagnosis: Other conditions such as hydrocephalus, vascular disease or cerebral palsy must be ruled out.
Treatment
Treatment of periventricular leukomalacia is complex and involves a comprehensive approach. It includes:
- General treatment: Supportive therapy to correct the condition of the newborn, including monitoring oxygen levels and body temperature.
- Pharmacological treatment: There are no specific drugs for PVL; symptom management agents such as muscle relaxants to reduce muscle tone are used.
- Surgical treatment: In cases of severe complications such as hydrocephalus, a shunt may need to be placed to drain the CSF.
- Other types of treatment: Rehabilitation therapy, physical therapy and speech therapy play an important role in recovery, especially in early childhood.
List of medications used to treat this disease
There are currently no specific medications registered for periventricular leukomalacia. However, the following medications may be used to manage symptoms:
- Diazepam (Sedative);
- Baclofen (Muscle relaxant);
- Paracetamol (Painkiller);
- Phenobarbital (Anticonvulsant);
- Zaguska (Medicines for improving cerebral circulation).
Disease monitoring
Monitoring the condition of children diagnosed with periventricular leukomalacia includes regular examinations by a neurologist and neuropsychologist. The main stages of monitoring are as follows:
- Assessment of child development up to 2 years of age;
- Clinical assessment and correction if necessary;
- Prognosis: Children who have had PVL may have a variety of consequences, from mild impairment to severe disability;
- Complications may include spastic paralysis, psychomotor delay, and speech problems.
Age-related features of the disease
Periventricular leukomalacia has its own age-related characteristics. At an early age (up to 2 years), there is a high risk of developing motor and cognitive impairment. In older children (2 to 5 years), difficulties with learning and social skills may first appear. In adolescents, the consequences of PVL may manifest themselves in social incompetence or emotional problems. Research shows that the severity of PVL correlates with functional ability in adulthood.
Questions and Answers
- What is periventricular leukomalacia?
This disease is characterized by damage to the white matter of the brain, which is most often seen in premature infants and is associated with a lack of oxygen. - What are the main risk factors for PVL?
Major risk factors include prematurity, low birth weight, and maternal infections during pregnancy. - How is PVL diagnosed?
Diagnostics includes ultrasound of the brain, clinical observations and assessment of the neurological status of the newborn. - What are the treatments for PVL?
Treatment includes supportive care, pharmacological support for symptom management, and rehabilitation measures. - What to do to monitor the condition of a child diagnosed with PVL?
Regular check-ups with a neurologist, assessment of the child's development and adjustment of treatment as needed.
